



## Therapeutic Approaches for Type 1 and Type 2 Diabetes

Guest Editors:

### Message from the Guest Editors

#### **Prof. Dr. Vasso Apostolopoulos**

Institute for Health and Sport,  
Victoria University, Melbourne,  
VIC 3011, Australia

Vasso.Apostolopoulos@  
vu.edu.au

#### **Dr. Vanessa Barriga**

Institute for Health and Sport,  
Victoria University, Melbourne,  
VIC, Australia

vanessa.barriga@live.vu.edu.au

Deadline for manuscript  
submissions:

**closed (15 December 2019)**

Type 1 diabetes (T1D) is a life threatening disease which requires daily injections of insulin. At present, there is no cure for T1D. This disease develops when white blood cells that normally protect the body from infections get a signal to destroy cells in the insulin-producing areas of the pancreas (beta cells); thus there is no insulin produced. The white blood cells, in particular T cells, are primarily responsible for this destruction. Some of the targets within the pancreas that the T cells recognise and attack are known and are used for therapeutics and vaccine purposes. B cells (auto-antibodies) have also been identified to damage the pancreas T1D patients.

Type 2 diabetes (T2D) is a progressive condition where beta cells in the pancreas still make insulin but not enough or the the body's cells can't respond properly to insulin that is made. This leads to high glucose levels. People with T2D are at risk of other co-morbid disorders including cardiovascular disease, mental health, inflammatory disorders and cancer.

This Special Issue is for reviews or original research papers on therapeutics against T1D and T2D.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:**— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPlus / SciFinder](#), and many [other databases](#).

**Journal Rank:** [JCR - Q2 \(Immunology\)](#)

## Contact Us

---

*Vaccines*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)